Physician profile
Jodilyn Jelsema
NPI 1518195460
$10,436.84
in general payments reported to CMS, 2019-2025
21 companies · $728 in 2025
The $728 reported for 2025 was more than what 89% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $1,320 · 2021: $924 · 2022: $1,919 · 2023: $4,154 · 2024: $1,162 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,779 · Travel and Lodging: $2,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,778.54 |
| Travel and Lodging | $2,265.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $6,136.81 | 2021-2025 | Xeomin |
| Abbvie INC. | $1,294.53 | 2021-2025 | |
| Allergan, INC. | $676.72 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $580.08 | 2019-2021 | |
| Revance Therapeutics, INC. | $342.89 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $230.14 | 2021-2025 | |
| Amgen INC. | $218.04 | 2020 | |
| Amarin Pharma, INC. | $175.06 | 2020-2021 | |
| Novo Nordisk INC | $140.97 | 2020-2022 | |
| Lilly USA, LLC | $134.24 | 2020-2021 | |
| Astellas Pharma US INC | $114.98 | 2020 | |
| Sanofi-Aventis U.S. LLC | $96.36 | 2019 | |
| Pfizer INC. | $95.44 | 2020 | |
| Janssen Pharmaceuticals, INC | $42.53 | 2020 | |
| Ibsa Pharma INC. | $39.81 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36.82 | 2020-2021 | |
| Genentech USA, INC. | $29.90 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.47 | 2020 | |
| Daiichi Sankyo INC. | $13.85 | 2020 | |
| Glaxosmithkline, LLC. | $11.18 | 2020 | |
| Merck Sharp & Dohme LLC | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodilyn Jelsema listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.